WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1985005623) AGENT FOR TREATING ARTERIOSCLEROSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1985/005623    International Application No.:    PCT/JP1985/000286
Publication Date: 19.12.1985 International Filing Date: 24.05.1985
IPC:
A61K 31/575 (2006.01), C07J 53/00 (2006.01)
Applicants: ZERIA SHINYAKU KOGYO KABUSHIKI KAISHA [JP/JP]; 10-11, Nihonbashi Kofunecho, Chuo-ku, Tokyo 103 (JP) (For All Designated States Except US).
INAGAKI, Tetsuya [JP/JP]; (JP) (For US Only).
AOKI, Hidemi [JP/JP]; (JP) (For US Only).
AIKAWA, Hiroyasu [JP/JP]; (JP) (For US Only).
SAKAMOTO, Koji [JP/JP]; (JP) (For US Only)
Inventors: INAGAKI, Tetsuya; (JP).
AOKI, Hidemi; (JP).
AIKAWA, Hiroyasu; (JP).
SAKAMOTO, Koji; (JP)
Agent: YAMADA, Tsunemitsu @; 2nd Yahagi Bldg., 5-3, Uchikanda 3-chome, Chiyoda-ku, Tokyo 101 (JP)
Priority Data:
59/106123 25.05.1984 JP
Title (EN) AGENT FOR TREATING ARTERIOSCLEROSIS
(FR) AGENT DE TRAITEMENT DE L'ARTERIOSCLEROSE
Abstract: front page image
(EN)An agent for treating arteriosclerosis, which contains as effective ingredient cycloartenol ferulate, a component of $g(g)-oryzanol. This agent shows excellent effects of lowering a total cholesterol level, a free cholesterol level, a neutral fat level, and a phospholipid level, and raising an HDL-cholesterol level (believed to be an arteriosclerosis alleviating factor) to remarkably reduce arteriosclerosis index with less liver troubles.
(FR)Agent de traitement de l'artériosclérose, contenant comme ingrédient efficace du férulate de cycloarténol, un composant du $g(g)-oryzanol. Cet agent possède l'excellente propriété d'abaisser le niveau global de cholestérol, le niveau du cholestérol libre, le niveau de graisses neutres et le niveau de phospholipides, et d'augmenter le niveau du cholestérol HDL (considéré être un facteur de soulagement de l'artériosclérose), permettant ainsi de réduire l'indice de l'artériosclérose tout en limitant les troubles du foie.
Designated States: US.
European Patent Office (BE, CH, DE, FR, GB, IT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)